Dear Subscribers,

I have had thousands of questions regarding my opinion of the new HPV vaccine. Here is the reason why I do not support the use of this vaccine on our daughters.

HPV Vaccine deaths total 11... Over 3500 Adverse events reported

Once you read the following you will be horrified we are using our daughters as guinea pigs in the HPV experiment. There have been 11 deaths from the vaccine so far and counting. Over 3500 adverse events have been reported and over 400 have been reported serious (including complications like Bells Palsy, seizures, paralysis, and Guillian-Barre Syndrome). Of the 42 women vaccinated with HPV while pregnant 18 have experienced complications from fetal abnormalities to miscarriages.

Most importantly, the lead researcher who spent 20 years developing the vaccine for HPV Diane M. Harper states that, "The HPV vaccine is not for younger women and that it is "silly" for anyone to be mandating it for them". She says, "The vaccine has not been tested for effectiveness in girls as young as 9 and it may not even protect them. And, in the worst-case scenario, instead of serving to reduce the numbers of cervical cancers within 25 years, such a vaccination crusade may actually cause the numbers to increase." Diane Harper, a scientist and professor states "Giving the vaccine to 11 year olds is a great big public health experiment.

...So what are we doing to our little girls?


What is HPV?

Human papillomavirus (HPV) is the name of a group of more than 100 different types of viruses. More than 40 types of HPV are sexually transmitted. These types can infect the genital areas of both men and women, including the skin of the penis, vulva, anus, and the lining of the vagina, cervix and rectum. The most important risk factor for developing cervical cancer is HPV infection of the cervix. Almost all cases of cervical cancer are linked to HPV infection. There are 15 of the more than 40 sexually transmitted HPV that can lead to the development of cervical cancer. HPV 16 and HPV 18 are thought to be responsible for about 70 percent of cervical cancers. HPV is transmitted through genital skin-to-skin contact and can appear years after exposure.

The Guardasil vaccine approved by Health Canada and the FDA in 2006 is thought to protect against HPV 16 and 18. The vaccine also protects against HPV 6 and 11, the most common lower risk types of HPV. HPV 6 and 11 cause 90% of genital warts. Infection with HPV low-risk 6 and 11 are not associated with an increased risk of cancer.

By age 50, fifty percent of women will have acquired sexually transmitted HPV infection. Most women will never know they have been infected because there are usually no symptoms. In most people, the body's immune system eliminates the infection. In 90 percent of cases those who acquire a cervical HPV infection the virus will not be detected after 2 years. When HPV is gone the cervical cells return to normal. Men and women can get HPV and pass it along without ever knowing it. Sometimes HPV is not destroyed by the immune system and the high risk types increase the risk of cancer.

The HPV vaccine is being recommended for girls and women from age 9 to 26 even though few girls were involved in the studies. 11,000 women took part in the vaccine trials. No minors were included in the Merck,Guardasil trials. The manufacturer states it is unclear how long the vaccine will provide protection. The vaccine only protects against 4 strains of HPV and women will still be at risk of cervical cancer from other HPV strains. GlaxoSmithKline will also be launching an HPV vaccine called Cervarix for HPV 16 and 18.

Although men carry the virus and can infect women no research was done on our boys and men being vaccinated. Studies are now being done to see if it prevents HPV infection in them. By vaccinating boys indirectly women will be protected from those HPV strains by preventing the spread. Again another experiment.. only this time with our boys.

Abby Lippman, a professor of epidemiology at McGill University, and colleagues, conducted a review of the current literature on the HPV the vaccine and summarize their conclusions in an editorial in the Canadian Medical Association Journal.

These researchers found that while it appears that the vaccine is highly effective in preventing infection with HPV types 16 and 18 it's still not clear whether reducing such infections will translate into fewer cervical cancer deaths in the long run. They note that rates of deaths from cervical cancer had been dropping in Canada for years anyway, because of the widespread availability of publicly-funded programs for Pap smear testing.

They also note that there are many gaps in knowledge about the vaccine:
  • It's not clear for how long the vaccine will be effective;
  • or whether a booster shot will be needed in later years;
  • and there is also a lack of data, they say, on the effectiveness of the HPV vaccine when given at the same time as other immunizations.
And they note that relatively few girls aged 9 to 15 years were enrolled in the clinical trials and the youngest of whom were followed for only 18 months. Yet girls in this age group represent the priority target population for mass vaccination.

There is a bias as all of the reported HPV vaccine trials, whether of Gardasil or its potential competitor Cervarix, were funded in whole or in part by the vaccine's manufacturer.
B Noting that Gardasil is the most expensive childhood vaccine proposed for mass use (it currently costs many hundreds of dollars per the 3 required doses), the authors point out that there haven't been any cost-effectiveness analyses to determine whether the proposed vaccination programs will result in fewer cancer deaths.

PAP Tests Reduce Cancer Rates

A simple PAP test can detect changes to the cervix. Read below for nutrients that can reverse an abnormal PAP or more importantly prevent abnormal PAPS and treat HPV in the first place.

HPV blood testing

An HPV test detects certain types of human papillomavirus (HPVs), depending on the test. A method for detecting the DNA of high-risk HPVs has recently been added to the range of clinical options for cervical cancer screening. In March 2003, the US FDA approved a "hybrid-capture" test, as a primary screening tool for detecting high-risk HPV infections that may lead to cervical cancer. This test was also approved for use as an adjunct to Pap testing, and may be ordered in response to abnormal Pap smear results. Adding the HPV test for all women over thirty improves the sensitivity of the cytology test alone to nearly 100%. According to the CDC there is currently no test commercially available to determine infection in men. Genital warts are the only visible sign of HPV in men, and can be identified with a visual check of the genital area.

What's more no one is telling you that we can protect women from the negative effects of HPV with Indole-3-carbinol and other nutrients.

16-hydroxyestrone and Cervical Cancer

Women with cervical dysplasia (noted by abnormal Pap tests) have higher levels of the estrogen metabolite 16-hydroxyestrone. A study in the International Journal of Cancer found a connection between the human papillomavirus (HPV) and high levels of 16-hydroxyestrone or a greater affinity for conversion of estrogens into this carcinogenic metabolite and the development of cervical cancer. Researchers suggested that the combined action of 16-hydroxyestrone and HPV promotes abnormal cell proliferation. Now scientists think the HPV virus actually uses the 16-hydroxyestrone to promote cancer cell development.

Indole-3-carbinol Reverses Abnormal PAPS

New research shows that indole-3-carbinol (I3C) can reverse abnormal cervical lesions before they have a chance to develop into cancer. In one of many studies, 30 women with CINII and CINIII cervical lesions took 200 mg of 13C daily for six months. 50 percent in the treatment group had complete regression of their lesions. None of the placebo group (those getting fake pills) had any change in their lesions.

Cervical dysplasia and cervical cancer can be prevented. Have your annual Pap smear, and make sure your mom has hers as well-too many women after menopause are not having annual tests. Pap tests save lives! Smart women take their multivitamin with minerals every day and include indole-3-carbinol which is found in ESTROSMART. I believe if every woman from the age of menstruation to death took ESTROSMART not only would we see a reduction in HPV induced abnormal PAPS but also reduction in breast cancer rates. Let's ensure all women have normal PAP smears with ESTROSMART.

Vitamin A

In a clinic-based case-control study to assess serum micronutrients as risk factors for cervical dysplasia, subjects in the lowest serum retinol quartile were at increased risk of CIN I abnormal cervical cells compared with women with high levels of retinol from vitamin A. Another reason to take MULTISMART everyday.

Vitamin C

Risk of type-specific, persistent HPV infection was lower among women reporting high intakes of vitamin C (500mg per day or more) than those with low vitamin C intakes. Another reason to take MULTISMART. The time it takes for HPV to be eliminated in the body was significantly shorter among women with the highest compared with the lowest serum levels of vitamin E. Another reason to take MULTISMART every day.

Folic acid

Women with high folic acid levels were less likely to become HPV test-positive. Women with higher folate status were significantly less likely to be repeatedly HPV test-positive and more likely to become test-negative. Studies have shown that lower levels of antioxidants coexisting with low levels of folic acid increases the risk of CIN development. Improving folate status in subjects at risk of getting infected or already infected with high-risk HPV may have a beneficial impact in the prevention of cervical cancer. Another reason to take MULTISMART every day.

Carotenoids (beta carotene, lycopene etc.)

Higher circulating levels of carotenoids were associated with a significant decrease in the clearance time of type-specific HPV infection, particularly during the early stages of infection. The likelihood of clearing a potential cancer-causing HPV infection is significantly higher with increasing levels of lycopene. A 56% reduction in HPV persistence was found in women with the highest plasma lycopene concentrations compared with women with the lowest plasma lycopene concentrations. This research suggests that consumption of lycopene may be protective against HPV persistence. Another reason to take MULTISMART every day.

CoQ10

Women who had either CIN or cervical cancer had markedly lower levels of coenzyme Q10 in their blood and in their cervical cells than the women who were healthy.

Fruits and vegetables

Higher levels of vegetable consumption were associated with a 54% decrease risk of HPV persistence. Consumption of papaya at least once a week was found to reverse persistent HPV infection.

Fish oil or DHA Algae (DHA)

In a 1999 study, DHA Docosahexaenoic acid inhibited growth of HPV16 cells. A strong immune system will also kill and destroy HPV before it has a chance to cause cancer.

Not only is the research clear that the new HPV vaccine is not safe, has not been thoroughly studied for its long term effects—but it is fundamentally wrong to use our daughters as guinea pigs for the pharmaceutical giants.

Read more about HPV...CLICK HERE

References:

  1. Walboomers JM, Jacobs MV, Manos MM, et al (1999). "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide". J. Pathol. 189 (1): 12-9. doi:<12::AID-PATH431>3.0.CO;2-F 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. PMID 10451482.
  2. Lowy DR, Schiller JT (2006). "Prophylactic human papillomavirus vaccines". J. Clin. Invest. 116 (5): 1167-73. doi:10.1172/JCI28607. PMID 16670757.
  3. Revzina NV, Diclemente RJ (2005). "Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review". International journal of STD & AIDS 16 (8): 528-37. doi:10.1258/0956462054679214. PMID 16105186. "The prevalence of HPV reported in the assessed studies ranged from 14% to more than 90%."
  4. McCullough, Marie. "Cancer-virus strains rarer than first estimated", The Philadelphia Inquirer, 2007-02-28. Retrieved on 2007-03-02.
  5. Brown, David. "Study finds more women than expected have HPV", San Francisco Chronicle, 2007-02-28. Retrieved on 2007-03-02. (originally published in the Washington Post as "More American Women Have HPV Than Previously Thought")
  6. Dunne EF, Unger ER, Sternberg M, et al (2007). "Prevalence of HPV infection among females in the United States". JAMA 297 (8): 813-9. doi:10.1001/jama.297.8.813. PMID 17327523.
  7. Baseman JG, Koutsky LA (2005). "The epidemiology of human papillomavirus infections". J. Clin. Virol. 32 Suppl 1: S16-24. doi:10.1016/j.jcv.2004.12.008. PMID 15753008. *Note: The authors state on page S17 "Overall, these DNA-based studies, combined with measurements of type-specific antibodies against HPV capsid antigens, have shown that most (>50%) sexually active women have been infected by one or more genital HPV types at some point in time."
  8. American Social Health Association - HPV Resource Center. Retrieved on 2007-08-17.
  9. STD Facts - HPV and Men. Retrieved on 2007-08-17.
  10. Frisch M, Smith E, Grulich A, Johansen C (2003). "Cancer in a population-based cohort of men and women in registered homosexual partnerships". Am. J. Epidemiol. 157 (11): 966-72. PMID 12777359. "However, the risk for invasive anal squamous carcinoma, which is believed to be caused by certain types of sexually transmitted human papillomaviruses, notably type 16, was significantly 31-fold elevated at a crude incidence of 25.6 per 100,000 person-years."
  11. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR (2006). "Prevalence of HPV infection among men: A systematic review of the literature". J. Infect. Dis. 194 (8): 1044-57. doi:10.1086/507432. PMID 16991079.
  12. What Men Need to Know About HPV (2006). Retrieved on 2007-04-04. "There is currently no FDA-approved test to detect HPV in men. That is because an effective, reliable way to collect a sample of male genital skin cells, which would allow detection of HPV, has yet to be developed."
  13. WebMD -- Error 404. Retrieved on 2007-08-17.
  14. STD Facts - HPV Vaccine (2006-08-01). Retrieved on 2007-08-17.
  15. Greer CE, Wheeler CM, Ladner MB, et al (1995). "Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts". J. Clin. Microbiol. 33 (8): 2058-63. PMID 7559948.
  16. Gearheart PA, Randall TC, Buckley RM Jr (2004). Human Papillomavirus. eMedicine.
  17. Parkin DM (2006). "The global health burden of infection-associated cancers in the year 2002". Int. J. Cancer 118 (12): 3030-44. doi:10.1002/ijc.21731. PMID 16404738.
  18. a b D'Souza G, Kreimer AR, Viscidi R, et al (2007). "Case-control study of human papillomavirus and oropharyngeal cancer". N. Engl. J. Med. 356 (19): 1944-56. doi:10.1056/NEJMoa065497. PMID 17494927.
  19. Greenblatt R.J. 2005. Human papillomaviruses: Diseases, diagnosis, and a possible vaccine. Clinical Microbiology Newsletter, 27(18), 139-145. Abstract available.
  20. Sinal SH, Woods CR (2005). "Human papillomavirus infections of the genital and respiratory tracts in young children". Seminars in pediatric infectious diseases 16 (4): 306-16. doi:10.1053/j.spid.2005.06.010. PMID 16210110.
  21. Gillison ML, Koch WM, Capone RB, et al (2000). "Evidence for a causal association between human papillomavirus and a subset of head and neck cancers". J. Natl. Cancer Inst. 92 (9): 709-20. PMID 10793107.
  22. Gillison ML (2006). "Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers". J. Clin. Oncol. 24 (36): 5623-5. doi:10.1200/JCO.2006.07.1829. PMID 17179099.
  23. Wu R, Sun S, Steinberg BM (2003). "Requirement of STAT3 activation for differentiation of mucosal stratified squamous epithelium". Mol. Med. 9 (3-4): 77-84. PMID 12865943.
  24. Moore CE, Wiatrak BJ, McClatchey KD, et al (1999). "High-risk human papillomavirus types and squamous cell carcinoma in patients with respiratory papillomas". Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 120 (5): 698-705. doi:10.1053/hn.1999.v120.a91773. PMID 10229596.
  25. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG (2000). "The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses". J. Virol. 74 (24): 11636-41. PMID 11090162.
  26. Schiffman M, Castle PE (2005). "The promise of global cervical-cancer prevention". N. Engl. J. Med. 353 (20): 2101-4. doi:10.1056/NEJMp058171. PMID 16291978.
  27. Cohen J (2005). "Public health. High hopes and dilemmas for a cervical cancer vaccine". Science 308 (5722): 618-21. doi:10.1126/science.308.5722.618. PMID 15860602.
  28. Noel J, Lespagnard L, Fayt I, Verhest A, Dargent J (2001). "Evidence of human papilloma virus infection but lack of Epstein-Barr virus in lymphoepithelioma-like carcinoma of uterine cervix: report of two cases and review of the literature". Hum. Pathol. 32 (1): 135-8. PMID 11172309.
  29. Edwards QT, Saunders-Goldson S, Morgan PD, Maradiegue A, Macri C (2005). "Vulvar intraepithelial neoplasia: varied signs, varied symptoms: what you need to know". Advance for nurse practitioners 13 (3): 49-52. PMID 15777042.
  30. Bolt J, Vo QN, Kim WJ, McWhorter AJ, Thomson J, Hagensee ME, Friedlander P, Brown KD, Gilbert J (2005). "The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms". Oral Oncol. 41 (10): 1013-20. PMID 16139561.
  31. [1], J Inflamm 2007;4.
  32. Chin-Hong PV, Vittinghoff E, Cranston RD, et al (2005). "Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study". J. Natl. Cancer Inst. 97 (12): 896-905. doi:10.1093/jnci/dji163. PMID 15956651.
  33. http://www.cdc.gov/STD/HPV/STDFact-HPV-and-men.htm#test [January 2007]
  34. Harper DM, Franco EL, Wheeler CM, et al (2006). "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial". Lancet 367 (9518): 1247-55. doi:10.1016/S0140-6736(06)68439-0. PMID 16631880.
  35. Cervical Cancer Vaccine Approved. WebMD. Retrieved on 2007-08-17.
  36. HPV and HPV Vaccine - HCP (2006-08-01). Retrieved on 2007-08-17.
  37. STD Facts - Human papillomavirus (HPV). Retrieved on 2007-08-17.
  38. Markus J. Steiner and Willard Cates, Jr. (2006). "Condoms and Sexually-Transmitted Infections". N. Engl. J. Med. 354 (25): 2642-3. [2]
  39. Winer RL, Hughes JP, Feng Q, et al (2006). "Condom use and the risk of genital human papillomavirus infection in young women". N. Engl. J. Med. 354 (25): 2645-54. doi:10.1056/NEJMoa053284. PMID 16790697. [Free online]
  40. Moscicki AB (2005). "Impact of HPV infection in adolescent populations". The Journal of adolescent health : official publication of the Society for Adolescent Medicine 37 (6 Suppl): S3-9. PMID 16310138.
  41. Bleeker MC, Berkhof J, Hogewoning CJ, et al (2005). "HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions". Br. J. Cancer 92 (8): 1388-92. doi:10.1038/sj.bjc.6602524. PMID 15812547.
  42. Planned Parenthood - HPV. Retrieved on 2007-08-17.
  43. Howett MK, Kuhl JP (2005). "Microbicides for prevention of transmission of sexually transmitted diseases". Curr. Pharm. Des. 11 (29): 3731-46. PMID 16305508.
  44. Buck CB, Thompson CD, Roberts JN, M�M, Lowy DR, Schiller JT (2006). "Carrageenan is a potent inhibitor of papillomavirus infection". PLoS Pathog. 2 (7): e69. PMID 16839203.
  45. Yeo AS, Schiff MA, Montoya G, Masuk M, van Asselt-King L, Becker TM (2000). "Serum micronutrients and cervical dysplasia in Southwestern American Indian women". Nutrition and cancer 38 (2): 141-50. PMID 11525590.
  46. Giuliano AR, Siegel EM, Roe DJ, et al (2003). "Dietary intake and risk of persistent human papillomavirus (HPV) infection: the Ludwig-McGill HPV Natural History Study". J. Infect. Dis. 188 (10): 1508-16. PMID 14624376.
  47. a b Goodman MT, Shvetsov YB, McDuffie K, et al (2007). "Hawaii cohort study of serum micronutrient concentrations and clearance of incident oncogenic human papillomavirus infection of the cervix". Cancer Res. 67 (12): 5987-96. doi:10.1158/0008-5472.CAN-07-0313. PMID 17553901.
  48. Kwasniewska A, Tukendorf A, Semczuk M (1997). "Content of alpha-tocopherol in blood serum of human Papillomavirus-infected women with cervical dysplasias". Nutrition and cancer 28 (3): 248-51. PMID 9343832.
  49. Piyathilake CJ, Henao OL, Macaluso M, et al (2004). "Folate is associated with the natural history of high-risk human papillomaviruses". Cancer Res. 64 (23): 8788-93. doi:10.1158/0008-5472.CAN-04-2402. PMID 15574793.
  50. Kwasniewska A, Tukendorf A, Gozdzicka-J򹤦iak A, Semczuk-Sikora A, Korobowicz E (2002). "Content of folic acid and free homocysteine in blood serum of human papillomavirus-infected women with cervical dysplasia". Eur. J. Gynaecol. Oncol. 23 (4): 311-6. PMID 12214730.
  51. Sedjo RL, Papenfuss MR, Craft NE, Giuliano AR (2003). "Effect of plasma micronutrients on clearance of oncogenic human papillomavirus (HPV) infection (United States)". Cancer Causes Control 14 (4): 319-26. PMID 12846362.
  52. Sedjo RL, Roe DJ, Abrahamsen M, et al (2002). "Vitamin A, carotenoids, and risk of persistent oncogenic human papillomavirus infection". Cancer Epidemiol. Biomarkers Prev. 11 (9): 876-84. PMID 12223432.
  53. Giuliano AR, Siegel EM, Roe DJ, et al (2003). "Dietary intake and risk of persistent human papillomavirus (HPV) infection: the Ludwig-McGill HPV Natural History Study". J. Infect. Dis. 188 (10): 1508-16. PMID 14624376.
  54. Giuliano AR, Papenfuss M, Nour M, Canfield LM, Schneider A, Hatch K (1997). "Antioxidant nutrients: associations with persistent human papillomavirus infection". Cancer Epidemiol. Biomarkers Prev. 6 (11): 917-23. PMID 9367065.
  55. Chen D, Auborn K (1999). "Fish oil constituent docosahexa-enoic acid selectively inhibits growth of human papillomavirus immortalized keratinocytes". Carcinogenesis 20 (2): 249-54. PMID 10069461.
  56. zur Hausen H, de Villiers EM (1994). "Human papillomaviruses". Annu. Rev. Microbiol. 48: 427-47. PMID 7826013.
Hormone Help Issue 22, Nov. 2007